Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29590221
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\29590221
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 PLoS+One
2018 ; 13
(3
): e0195122
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Andexanet alfa effectively reverses edoxaban anticoagulation effects and
associated bleeding in a rabbit acute hemorrhage model
#MMPMID29590221
Lu G
; Pine P
; Leeds JM
; DeGuzman F
; Pratikhya P
; Lin J
; Malinowski J
; Hollenbach SJ
; Curnutte JT
; Conley PB
PLoS One
2018[]; 13
(3
): e0195122
PMID29590221
show ga
INTRODUCTION: Increasing use of factor Xa (FXa) inhibitors necessitates effective
reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant
human FXa, rapidly reverses the anticoagulation effects of direct and indirect
FXa inhibitors. OBJECTIVE: To evaluate the ability of andexanet to reverse
anticoagulation in vitro and reduce bleeding in rabbits administered edoxaban.
MATERIALS AND METHODS: In vitro studies characterized the interaction of
andexanet with edoxaban and its ability to reverse edoxaban-mediated anti-FXa
activity. In a rabbit model of surgically induced, acute hemorrhage, animals
received edoxaban vehicle+andexanet vehicle (control), edoxaban (1
mg/kg)+andexanet vehicle, edoxaban+andexanet (75 mg, 5-minute infusion, 20
minutes after edoxaban), or edoxaban vehicle+andexanet prior to injury. RESULTS:
Andexanet bound edoxaban with high affinity similar to FXa. Andexanet rapidly and
dose-dependently reversed the effects of edoxaban on FXa activity and coagulation
pharmacodynamic parameters in vitro. In edoxaban-anticoagulated rabbits,
andexanet reduced anti-FXa activity by 82% (from 548±87 to 100±41 ng/ml;
P<0.0001), mean unbound edoxaban plasma concentration by ~80% (from 100±10 to
21±6 ng/ml; P<0.0001), and blood loss by 80% vs. vehicle (adjusted for control,
2.6 vs. 12.9 g; P = 0.003). The reduction in blood loss correlated with the
decrease in anti-FXa activity (r = 0.6993, P<0.0001) and unbound edoxaban (r =
0.5951, P = 0.0035). CONCLUSION: These data demonstrate that andexanet rapidly
reversed the anticoagulant effects of edoxaban, suggesting it could be clinically
valuable for the management of acute and surgery-related bleeding. Correlation of
blood loss with anti-FXa activity supports the use of anti-FXa activity as a
biomarker for assessing anticoagulation reversal in clinical trials.